Renal medullary carcinoma, or RMC, is a rare yet aggressive type of kidney cancer. It usually affects young people -- mostly those who have sickle cell disease or sickle cell trait and have African ...
Covalent inhibitors of the common mutant isoform of RAS, KRAS(G12C), have begun to unlock the potential of targeting RAS oncoproteins, but limitations to this approach remain. Now, two papers ...
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in ...
REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...
9don MSN
Myeloid mimicry enables kidney tumors to resist immunotherapy and worsen rapidly, study finds
Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an ...
Revolution Medicines, Inc. stock has more than doubled since the market initially reacted negatively to a clinical update on its lead asset RMC-6236 in October 2023. The company's RAS(ON) inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results